Vascular endothelial growth factor C as a predictor of early recurrence and poor prognosis of resected stage I non-small cell lung cancer.
- Author:
Shuo Chueh CHEN
1
;
Chuen Ming SHIH
;
Guan Chin TSENG
;
Wei Erh CHENG
;
Jean CHIOU
;
Michael HSIAO
;
Min Liang KUO
;
Jen Liang SU
;
Chih Yi CHEN
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Aged, 80 and over; Biomarkers; blood; Carcinoma, Non-Small-Cell Lung; blood; mortality; pathology; surgery; Disease-Free Survival; Female; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Analysis; Taiwan; Vascular Endothelial Growth Factor A; blood; metabolism
- From:Annals of the Academy of Medicine, Singapore 2011;40(7):319-324
- CountrySingapore
- Language:English
-
Abstract:
INTRODUCTIONStage I non-small cell lung cancer (NSCLC) is potentially curable after completely resection, but early recurrence may infl uence prognosis. This study hypothesises that vascular endothelial growth factor C (VEGF-C) plays a key role in predicting early recurrence and poor survival of patients with stage I NSCLC.
MATERIALS AND METHODSThe expression of VEGF-C was immuno-histochemically (IHC) analysed in tumour samples of primary stage I NSCLC and correlated to early recurrence (< 36 months), disease-free survival, and overall survival in all 49 patients.
RESULTSEarly recurrence was identifi ed in 16 patients (33%), and the early recurrence rate in strong and weak VEGF-C activity was significantly different (P = 0.016). VEGF-C was also an independent risk factor in predicting early recurrence (HR = 3.98, P = 0.02). Patients with strong VEGF-C staining also had poor 3-year disease-free survival (P = 0.008) and overall survival (P = 0.007).
CONCLUSIONStrong VEGF-C IHC staining could be a biomarker for predicting early recurrence and poor prognosis of resected stage I NSCLC, if the results of the present study are confirmed in a larger study. A more aggressive adjuvant therapy should be used in this group of patients.
